Boehringer Just Validated the TAM for Hidden-Condition Detection in Vet Tech
Boehringer Ingelheim's "Going Beyond" survey of 1,046 veterinarians across 51 countries found 87% of pet vets cite hidden conditions detection as the most overlooked part of their role. The data functions as demand-side TAM validation for any company building early-detection vet tech.
Eighty-seven percent of pet veterinarians worldwide say spotting hidden health problems and pain is the most overlooked part of their job, according to a new Boehringer Ingelheim survey of 1,046 vets across 51 countries. The number is the most useful demand-side signal published this year for any startup building clinical decision support, AI-assisted diagnostics, or wearable monitoring for veterinary practice.
Boehringer survey: 87% of pet vets say hidden conditions are most overlooked
Boehringer Ingelheim Animal Health published the survey on May 25 as part of its "Going Beyond" campaign, now in its second year. The survey was conducted in March and April 2026 with 1,046 qualifying veterinary professionals across 51 countries and was structured to identify the aspects of veterinary care that practitioners themselves believe are least visible to the public.
Three headline findings.
Among species-specific veterinarians, 87% of pet veterinarians cited "spotting hidden health problems and pain" as the most overlooked aspect of their role. The same answer landed at 60% among equine veterinarians, where the survey also captured "using a horse's environment and clinical history to predict risk" at 42%.
Livestock veterinarians identified "protecting food-chain safety" at 65% and "surveillance programs to limit spread of disease" at 62% as their most overlooked contributions.
The survey carries endorsements from the World Small Animal Veterinary Association, the American Association of Equine Practitioners, the World Association for Buiatrics, and the American Association of Swine Veterinarians. Quoted leaders include Dr. Jim Berry, President of WSAVA, Dr. Sarah Reuss, President of AAEP, and Arcangelo Gentile, President of the World Association for Buiatrics.
Boehringer's framing positions the data as a public-awareness narrative. The campaign exists to surface the invisible expertise of veterinary professionals. The operator read is different. The 87% figure is a market signal.
Why the data is the demand-side TAM for vet decision support tools
For any company building tools that help veterinarians identify conditions earlier (wearables, AI-assisted imaging, point-of-care diagnostics, behavioral monitoring, clinical decision support software), Boehringer just published the market validation slide.
When 87% of practitioners across 51 countries identify a specific work function as the most underrecognized part of what they do, the data implies four things at once.
The unmet need is universal. This is not a U.S. or European pattern. The 87% figure spans 51 countries. A product solving the hidden-conditions detection problem has global TAM, not just developed-market TAM.
Practitioners themselves frame the problem. Survey data from vendors, conference panels, or trade publications can be questioned for selection bias. This data comes from veterinarians naming their own most-overlooked work function. The framing is endogenous, which makes it more durable.
The major associations have committed reputational capital to the framing. WSAVA, AAEP, and the World Association for Buiatrics endorsing this campaign means clinical decision support tools that align with the framing (early detection, hidden pain, preventive care) have an easier path to association endorsement, CE credit integration, and standards body validation.
The world's largest animal health company is amplifying it. Boehringer's commercial portfolio overlaps with the problem. Vaccines, parasite-control products, and pain therapeutics all benefit from earlier detection of the conditions they treat. Publishing this data is a strategic choice that signals where Boehringer expects clinical conversations to move.
The category of companies positioned to capture this is already forming. The 2025-2026 cohort of vet tech includes SignalPET on AI-assisted radiology, Maven Pet and PetPace on wearable monitoring, Mars Waltham on periodontal AI, VolitionRx on Nu.Q canine cancer screening, and a wave of clinical decision support and admin AI tools like Vetnio. Tether (tether.pet), whose tagline reads "Know Before They Show," is building specifically for the early hidden-condition detection problem the Boehringer survey names.
For operators in vet tech, the implications are concrete.
The clinical decision support and early-detection category just got a piece of demand-side validation that does not depend on vendor-generated data. The data sits underneath any pitch to vet practices, vet groups, or animal health strategics. It is reusable for years.
For vet practice operators, the implication is operational. The work the survey identifies as most overlooked (spotting hidden conditions and pain) is also the work that drives downstream revenue. Earlier detection of dental disease, periodontal disease, kidney disease, osteoarthritis, and behavioral pain expands wellness visit value, generates downstream treatment revenue, and improves outcomes data. The opportunity to elevate this work is also the opportunity to grow average revenue per patient.
For animal health strategics, the implication is competitive. Boehringer is positioning around early detection at a campaign level. Zoetis, Elanco, Merck Animal Health, and Mars-owned animal health businesses can either match the framing or cede it. The campaign is two years in, which means competitors have had time to respond and have not, materially. That gap may compress over the next 12 months as competitors fund their own surveys, partnerships, or product launches around the same problem.
What the next wave of vet tech will need to prove to capture it
Three signals over the next 12 to 18 months will tell operators which vet tech companies actually capture this demand.
Clinical study data showing earlier detection translates to outcomes. The 87% survey number is a demand signal. It is not a proof-of-value signal. Companies in the hidden-conditions detection category (wearables, AI imaging, point-of-care diagnostics) will need to publish or contribute to peer-reviewed clinical data showing their tools meaningfully accelerate detection of clinically actionable conditions. Maven Pet, PetPace, SignalPET, Tether, and other emerging entrants should be evaluated on the strength and recency of their clinical evidence, not on the strength of their marketing positioning.
Association integration and CE credit pathways. WSAVA, AAEP, and other major associations endorsing Boehringer's framing means the path to association endorsement is open for products that align. Companies that secure CE credit integration, conference programming, or standards body recognition will compound credibility faster than those relying on direct-to-clinic sales motion alone.
Animal health strategic partnership announcements. Boehringer is signaling where it wants the clinical conversation to move. If it follows the framing with strategic investments, licensing deals, or acquisitions of early-detection vet tech in the next 12 months, the survey was the precursor. Watch for animal health strategics (Boehringer, Zoetis, Elanco, Merck, IDEXX) to announce partnerships or acquisitions that pull early-detection technology into their broader portfolios.
The survey is published as awareness content. It functions as something more useful: a TAM validation slide that any company building in the early-detection lane can use, citation-ready, for the next two years. That is the more important read.
Other News
More stories shaping the pet industry this week. From funding rounds and product launches to regulatory shifts and retail strategy, stay ahead of what's driving the market.
Spot & Tango Doubles UnKibble Capacity With a Second $20M Bet on Owned Manufacturing
Spot & Tango announced a $20M+ expansion of its Allentown, Pennsylvania manufacturing facility on June 2, doubling production capacity for its best-selling UnKibble product and adding 50 jobs. The expansion brings total invested capital in the owned plant to north of $40M and locks in a vertically integrated bet that runs counter to the co-manufacturing playbook most DTC fresh pet food brands follow.
Fi Just Boxed Itself Into a Two-Way Pet GPS Race in Europe
Fi expanded its connected pet collar to a 38-country footprint on June 2, adding nine new European paid markets including Finland, Sweden, Denmark, and the Netherlands. The expansion lands three weeks after Bending Spoons closed its acquisition of Tractive — Fi's largest global competitor — in a deal valued in the high three-digit millions of euros. The U.S.-native pet GPS category is now in a three-way international race with Tractive and Life360.
Elanco Says Pet Spending Is a "Protected Budget Item." The Number Behind That Claim Is 7%.
Elanco released new consumer research on June 3 showing 91% of U.S. pet owners maintained or increased pet health and wellness spending through the recent inflation cycle, with 38% spending more. The company pegged 2025 animal health industry growth at 7% — up from the 20-year 5% trend — and projects the global market grows from $42B to $60B over the next decade. The release is the most useful new data point in the pet category resilience story since APPA's 2026 forecast.